BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17:1507-1514. [PMID: 12823153 DOI: 10.1046/j.1365-2036.2003.01496.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Gao W, Zhang X, Yin Y, Yu S, Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol 2021;35:20587384211030397. [PMID: 34250840 DOI: 10.1177/20587384211030397] [Reference Citation Analysis]
2 Holtmann G, Bigard MA, Malfertheiner P, Pounder R. Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD. Int J Clin Pharm. 2011;33:493-500. [PMID: 21472476 DOI: 10.1007/s11096-011-9489-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
3 Sanaka M, Anjiki H, Yamamoto T, Kuyama Y. Rabeprazole delays gastric emptying of a nutrient liquid. J Gastroenterol Hepatol 2007;22:1806-9. [DOI: 10.1111/j.1440-1746.2006.04763.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
4 Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2012;35:810-818. [PMID: 22324425 DOI: 10.1111/j.1365-2036.2012.05014.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
5 Robinson M. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications. Aliment Pharmacol Ther. 2004;20 Suppl 6:1-10. [PMID: 15496213 DOI: 10.1111/j.1365-2036.2004.02160.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
6 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 15.7] [Reference Citation Analysis]
7 Bakheit AH, Al-Kahtani HM, Albraiki S. Rabeprazole: A comprehensive profile. Profiles Drug Subst Excip Relat Methodol 2021;46:137-83. [PMID: 33461697 DOI: 10.1016/bs.podrm.2020.07.003] [Reference Citation Analysis]
8 Yamagishi H, Koike T, Ohara S, Horii T, Kikuchi R, Kobayashi S, Abe Y, Iijima K, Imatani A, Suzuki K, Hishinuma T, Goto J, Shimosegawa T. Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole. World J Gastroenterol 2008; 14(15): 2406-2410 [PMID: 18416470 DOI: 10.3748/wjg.14.2406] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005;59:709-715. [PMID: 15924600 DOI: 10.1111/j.1368-5031.2005.00517.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
10 Guimarães EV, Guerra PV, Penna FJ. Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole. Ther Clin Risk Manag 2010;6:531-7. [PMID: 21063463 DOI: 10.2147/TCRM.S14425] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Wang HH, Chou JW, Liao KF, Lin ZY, Lai HC, Hsu CH, Chen CB. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. World J Gastroenterol 2005; 11(11): 1680-1684 [PMID: 15786549 DOI: 10.3748/wjg.v11.i11.1680] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
12 Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Review of Anti-infective Therapy 2014;3:863-70. [DOI: 10.1586/14787210.3.6.863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
13 Fock K, Teo E, Ang T, Chua T, Ng T, Tan Y. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: A randomized, double-blind study in urban Asia. World J Gastroenterol 2005; 11(20): 3091-3098 [PMID: 15918196 DOI: 10.3748/wjg.v11.i20.3091] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
14 Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, Lou Y, Lee EJ. Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration. Journal of Pharmaceutical Sciences 2010;99:1046-62. [DOI: 10.1002/jps.21860] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
15 Oda K, Iwakiri R, Hara M, Watanabe K, Danjo A, Shimoda R, Kikkawa A, Ootani A, Sakata H, Tsunada S. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci. 2005;50:1921-1926. [PMID: 16187198 DOI: 10.1007/s10620-005-2962-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
16 Robinson M. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment Pharmacol Ther. 2004;20 Suppl 6:30-37. [PMID: 15496216 DOI: 10.1111/j.1365-2036.2004.02163.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
17 Hirota K, Imai A, Kudo M, Hashimoto H, Kushikata T. Efficacy of a single 24-hour pre-anesthetic dose of proton pump inhibitors. Journal of Gastroenterology and Hepatology 2009;24:1244-7. [DOI: 10.1111/j.1440-1746.2009.05850.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19-31. [PMID: 18925391 DOI: 10.1007/s00228-008-0576-5] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 9.6] [Reference Citation Analysis]
19 Dadabhai A, Friedenberg FK. Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opin Drug Saf 2009;8:119-26. [PMID: 19236223 DOI: 10.1517/14740330802622892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
20 Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol. 2005;100:1696-1701. [PMID: 16086704 DOI: 10.1111/j.1572-0241.2005.50019.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
21 Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu L, Delchier JC, Bonnot-Marlier S. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther. 2004;20:899-907. [PMID: 15479362 DOI: 10.1111/j.1365-2036.2004.02176.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
22 Irani S, Krevsky B, Desipio J, Kim-jaffe J, Maqbool S, Fisher RS. Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole: PROTECTION OF THE GASTRODUODENAL MUCOSA FROM ASA. Alimentary Pharmacology & Therapeutics 2008;27:498-503. [DOI: 10.1111/j.1365-2036.2008.03600.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20:181-188. [PMID: 15233698 DOI: 10.1111/j.1365-2036.2004.01999.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
24 Bytzer P, Blum AL. Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:389-398. [PMID: 15298632 DOI: 10.1111/j.1365-2036.2004.02093.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
25 Lim P, Goh K. Review Article: Efficacy and safety of rabeprazole in treating gastroesophageal reflux disease. J Gastroenterol Hepatol 2004;19:S61-8. [DOI: 10.1111/j.1440-1746.2004.03592.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123:47-53. [PMID: 20102991 DOI: 10.1016/j.amjmed.2009.05.032] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
27 Zhang H, Zhang X, Liu J, Sun L, Shen Y, Zhou C, Zhang H, Xie L, Chen J, Liu Y, Wang Y. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacological Research 2020;152:104606. [DOI: 10.1016/j.phrs.2019.104606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
28 Robinson M, Barone J. Review article: comparative pharmacodynamic review of rabeprazole - focus on day 1 data. Aliment Pharmacol Ther Symp Series 2006;2:315-26. [DOI: 10.1111/j.1746-6342.2006.00062.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Yamano HO, Matsushita HO, Yanagiwara S. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. J Gastroenterol Hepatol 2008;23:534-40. [PMID: 17725594 DOI: 10.1111/j.1440-1746.2007.05104.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
30 Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol. 2012;6:423-435. [PMID: 22928894 DOI: 10.1586/egh.12.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
31 Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401. [PMID: 19583455 DOI: 10.2165/00003495-200969100-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
32 Vo L, Simonian HP, Doma S, Fisher RS, Parkman HP. The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2005;21:1321-30. [DOI: 10.1111/j.1365-2036.2005.02489.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
33 Tolman KG, Täubel J, Warrington S, Chiu YL, Pilmer BL, Pan WJ. Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. Clin Drug Investig 2006;26:21-8. [PMID: 17163231 DOI: 10.2165/00044011-200626010-00003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
34 Wang Y, Yuan Y, Meng L, Fan H, Xu J, Zhang H, Wang M, Yuan H, Ou N, Zhang H, Chao Y, Shi R. Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. Eur J Clin Pharmacol 2011;67:25-31. [PMID: 21110014 DOI: 10.1007/s00228-010-0949-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
35 Karamanolis G, Theofanidou I, Yiasemidou M, Giannoulis E, Triantafyllou K, Ladas SD. A glass of water immediately increases gastric pH in healthy subjects. Dig Dis Sci 2008;53:3128-32. [PMID: 18473176 DOI: 10.1007/s10620-008-0301-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
36 Warrington S, Baisley K, Lee D, Lomax K, Delemos B, Boyce M, Morocutti A. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Aliment Pharmacol Ther. 2007;25:511-517. [PMID: 17270007 DOI: 10.1111/j.1365-2036.2006.03196.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
37 Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol. 2010;25:1618-1625. [PMID: 20880169 DOI: 10.1111/j.1440-1746.2010.06408.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
38 Armstrong D, James C, Camacho F, Chen Y, Horbay GL, Teixeira B, Husein-Bhabha FA. Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2007;25:185-96. [PMID: 17116123 DOI: 10.1111/j.1365-2036.2006.03160.x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
39 Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, Vavasseur F, Taccoen A, Fiorentini P, Homerin M. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005;21:575-82. [PMID: 15740541 DOI: 10.1111/j.1365-2036.2005.02381.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
40 Wang HS, Oh DS, Anderson A, Nieto J, Tien P, Ohning G, Pisegna JR. Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity. Gut Liver 2008;2:30-8. [PMID: 20485608 DOI: 10.5009/gnl.2008.2.1.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47:1-6. [PMID: 18076214 DOI: 10.2165/00003088-200847010-00001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
42 Devault KR, Talley NJ. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol 2009;6:524-32. [DOI: 10.1038/nrgastro.2009.125] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
43 Xie J, Fan L, Xiong L, Chen P, Wang H, Chen H, Zhao J, Xu Z, Geng L, Xu W, Gong S. Rabeprazole inhibits inflammatory reaction by inhibition of cell pyroptosis in gastric epithelial cells. BMC Pharmacol Toxicol 2021;22:44. [PMID: 34266494 DOI: 10.1186/s40360-021-00509-7] [Reference Citation Analysis]
44 Lee JH, Jung HY, Choi KD, Song HJ, Lee GH, Kim JH. The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole. Gut Liver. 2010;4:201-206. [PMID: 20559522 DOI: 10.5009/gnl.2010.4.2.201] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
45 Belhocine K, Vavasseur F, Volteau C, Flet L, Touchefeu Y, Bruley des Varannes S. Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. BMC Gastroenterol. 2014;14:128. [PMID: 25027286 DOI: 10.1186/1471-230X-14-128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 de Korwin J, Ducrotté P, Vallot T. Les nouveaux inhibiteurs de la pompe à protons, un progrès dans la prise en charge des maladies acido-peptiques ? La Presse Médicale 2004;33:746-54. [DOI: 10.1016/s0755-4982(04)98731-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Calvet X, Gomollón F. What is potent acid inhibition, and how can it be achieved? Drugs. 2005;65 Suppl 1:13-23. [PMID: 16335854 DOI: 10.2165/00003495-200565001-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
48 García-Torres I, de la Mora-de la Mora I, Marcial-Quino J, Gómez-Manzo S, Vanoye-Carlo A, Navarrete-Vázquez G, Colín-Lozano B, Gutiérrez-Castrellón P, Sierra-Palacios E, López-Velázquez G, Enríquez-Flores S. Proton pump inhibitors drastically modify triosephosphate isomerase from Giardia lamblia at functional and structural levels, providing molecular leads in the design of new antigiardiasic drugs. Biochim Biophys Acta 2016;1860:97-107. [PMID: 26518348 DOI: 10.1016/j.bbagen.2015.10.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
49 Armstrong D. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther. 2004;20 Suppl 5:19-26; discussion 38-39. [PMID: 15456460 DOI: 10.1111/j.1365-2036.2004.02140.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
50 Nawaz MS. Validation and application of a new reversed phase HPLC method for in vitro dissolution studies of rabeprazole sodium in delayed-release tablets. J Anal Methods Chem 2013;2013:976034. [PMID: 24062966 DOI: 10.1155/2013/976034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis. 2005;37:741-750. [PMID: 16024305 DOI: 10.1016/j.dld.2005.04.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
52 Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003;63:2739-54. [PMID: 14664653 DOI: 10.2165/00003495-200363240-00004] [Cited by in Crossref: 117] [Cited by in F6Publishing: 102] [Article Influence: 6.9] [Reference Citation Analysis]
53 Anjiki H, Sanaka M, Kuyama Y. Dual effects of rabeprazole on solid-phase gastric emptying assessed by the 13C-octanoate breath test. Digestion 2005;72:189-94. [PMID: 16179787 DOI: 10.1159/000088465] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
54 Ono S, Kato M, Ono Y, Imai A, Yoshida T, Shimizu Y, Asaka M. Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules. J Gastroenterol Hepatol. 2009;24:639-645. [PMID: 19032447 DOI: 10.1111/j.1440-1746.2008.05644.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
55 Thjodleifsson B. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Expert Opinion on Pharmacotherapy 2005;5:137-49. [DOI: 10.1517/14656566.5.1.137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
56 Gu M, Zhang Y, Zhou X, Ma H, Yao H, Ji F. Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncol Lett 2014;8:1739-44. [PMID: 25202402 DOI: 10.3892/ol.2014.2354] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
57 Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther 2005;22 Suppl 3:20-4. [PMID: 16303033 DOI: 10.1111/j.1365-2036.2005.02714.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
58 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
59 Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol. 2012;5:49-59. [PMID: 22649281 DOI: 10.2147/ceg.s23926] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
60 Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O, Pariente A, Tocque E, Bonnot-Marlier S. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther. 2005;21:805-812. [PMID: 15801915 DOI: 10.1111/j.1365-2036.2005.02413.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
61 Katz PO. Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006;23 Suppl 1:3-11. [PMID: 16483265 DOI: 10.1111/j.1365-2036.2006.02801.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
62 de Boer W, de Wit N, Geldof H, Hazelhoff B, Bergmans P, Smout A, Tytgat G. Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? Scand J Gastroenterol 2006;41:1147-54. [PMID: 16990199 DOI: 10.1080/00365520600741546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
63 Varannes SBD, Sacher-Huvelin S, Vavasseur F, Masliah C, Rhun ML, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting. World J Gastroenterol 2006; 12(16): 2569-2573 [PMID: 16688803 DOI: 10.3748/wjg.v12.i16.2569] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
64 Furuta K, Adachi K, Ohara S, Morita T, Tanimura T, Koshino K, Kinoshita Y. Relationship between the Acid-Inhibitory Effects of Two Proton Pump Inhibitors and CYP2C19 Genotype in Japanese Subjects: A Randomized Two-Way Crossover Study. J Int Med Res 2010;38:1473-83. [DOI: 10.1177/147323001003800430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
65 Ren S, Park M, Sah H, Lee B. Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium. International Journal of Pharmaceutics 2008;350:197-204. [DOI: 10.1016/j.ijpharm.2007.08.035] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
66 Tonini M, Vigneri S, Neri M, Cuomo R, Savarino V, Pace F. Potential Options to Optimize Therapy of Gastroesophageal Reflux Disease with Proton Pump Inhibitors. Digestion 2008;76:171-8. [DOI: 10.1159/000111985] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
67 Louw JA, Marks I(. Peptic ulcer disease: . Current Opinion in Gastroenterology 2004;20:533-7. [DOI: 10.1097/00001574-200411000-00005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
68 Takahashi F, Yoshitake N, Akima T, Kino H, Nakano M, Tsuchida C, Tsuchida K, Tominaga K, Sasai T, Masuyama H. A second-look endoscopy may not reduce the bleeding after endoscopic submucosal dissection for gastric epithelial neoplasm. BMC Gastroenterol. 2014;14:152. [PMID: 25148855 DOI: 10.1186/1471-230x-14-152] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
69 Goh K. "On-demand" therapy for gastroesophageal reflux disease: Are current proton pump inhibitors good candidates? J Gastroenterol Hepatol 2006;21:S115-8. [DOI: 10.1111/j.1440-1746.2006.04714.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Javid G, Zargar SA, U-Saif R, Khan BA, Yatoo GN, Shah AH, Gulzar GM, Sodhi JS, Khan MA. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. J Gastroenterol Hepatol. 2009;24:1236-1243. [PMID: 19682194 DOI: 10.1111/j.1440-1746.2009.05900.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
71 Zannikos PN, Doose DR, Leitz GJ, Rusch S, Gonzalez MD, Solanki B, Haddad I, Mulberg AE. Pharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2011;52:691-701. [PMID: 21478756 DOI: 10.1097/MPG.0b013e318207834d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
72 Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. Aliment Pharmacol Ther. 2004;20 Suppl 6:11-19. [PMID: 15496214 DOI: 10.1111/j.1365-2036.2004.02161.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
73 Yang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol. 2010;6:29-41. [PMID: 19968574 DOI: 10.1517/17425250903386251] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
74 Ivashkin VT, Maev IV, Trukhmanov AS, Lapina TL, Storonova OA, Zayratyants OV, Dronova OB, Kucheryavyy YA, Pirogov SS, Sayfutdinov RG, Uspenskiy YP, Sheptulin AA, Andreev DN, Rumyantseva DE. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:70-97. [DOI: 10.22416/1382-4376-2020-30-4-70-97] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 17.0] [Reference Citation Analysis]
75 Ando T, Ishikawa T, Kokura S, Naito Y, Yoshida N, Yoshikawa T. Endoscopic Analysis of Gastric Ulcer after One Week's Treatment with Omeprazole and Rabeprazole in Relation to CYP2C19 Genotype. Dig Dis Sci 2008;53:933-7. [DOI: 10.1007/s10620-007-9965-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
76 Kuwayama H, Asaka M, Sugiyama T, Fukuda Y, Aoyama N, Hirai Y, Fujioka T. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment Pharmacol Ther. 2007;25:1105-1113. [PMID: 17439512 DOI: 10.1111/j.1365-2036.2007.03298.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
77 Uedo N, Takeuchi Y, Yamada T, Ishihara R, Ogiyama H, Yamamoto S, Kato M, Tatsumi K, Masuda E, Tamai C, Higashino K, Iishi H, Tatsuta M. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol. 2007;102:1610-1616. [PMID: 17403076 DOI: 10.1111/j.1572-0241.2007.01197.x] [Cited by in Crossref: 141] [Cited by in F6Publishing: 132] [Article Influence: 10.1] [Reference Citation Analysis]
78 Miki M, Adachi K, Azumi T, Koshino K, Furuta K, Kinoshita Y. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study. Aliment Pharmacol Ther 2006;24:1445-51. [PMID: 17032285 DOI: 10.1111/j.1365-2036.2006.03140.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
79 Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur J Clin Pharmacol 2006;62:685-91. [PMID: 16850327 DOI: 10.1007/s00228-006-0148-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
80 Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, Katelaris P, Tutuian RI, Castell DO. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs 2017;77:547-61. [PMID: 28233274 DOI: 10.1007/s40265-017-0712-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
81 Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N; ROSE Trial Investigators. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol 2006;41:1132-40. [PMID: 16990197 DOI: 10.1080/00365520600615781] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
82 Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers: COMBINED ANALYSIS OF RABEPRAZOLE VS. ESOMEPRAZOLE ON INTRAGASTRIC pH. Alimentary Pharmacology & Therapeutics 2007;25:501-10. [DOI: 10.1111/j.1365-2036.2006.03221.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
83 Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors - focus on pKa and metabolism. Aliment Pharmacol Ther Symp Series 2006;2:340-50. [DOI: 10.1111/j.1746-6342.2006.00065.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
84 Maiti R, Jaida J, Israel PL, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. J Pharmacol Pharmacother 2011;2:150-7. [PMID: 21897706 DOI: 10.4103/0976-500X.83278] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
85 Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528-534. [PMID: 19006606 DOI: 10.1007/s11894-008-0098-4] [Cited by in Crossref: 192] [Cited by in F6Publishing: 163] [Article Influence: 16.0] [Reference Citation Analysis]
86 Choudhary S, Jain A, Amin MCIM, Mishra V, Agrawal GP, Kesharwani P. Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer. Colloids and Surfaces B: Biointerfaces 2016;141:268-77. [DOI: 10.1016/j.colsurfb.2016.01.048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
87 Saremi K, Rad SK, Tayeby F, Abdulla MA, Karimian H, Majid NA. Gastroprotective activity of a novel Schiff base derived dibromo substituted compound against ethanol-induced acute gastric lesions in rats. BMC Pharmacol Toxicol 2019;20:13. [PMID: 30770761 DOI: 10.1186/s40360-019-0292-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
88 Orr WC. Therapeutic options in the treatment of nighttime gastroesophageal reflux. Digestion 2005;72:229-38. [PMID: 16319458 DOI: 10.1159/000089957] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
89 Tonini M, De Giorgio R, De Ponti F. Progress with novel pharmacological strategies for gastro-oesophageal reflux disease. Drugs. 2004;64:347-361. [PMID: 14969571 DOI: 10.2165/00003495-200464040-00001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
90 Cutler A, Robinson M, Murthy A, Delemos B. Rabeprazole 20 mg for Erosive Esophagitis-Associated Symptoms in a Large, Community-Based Study: Additional Results. Dig Dis Sci 2010;55:338-45. [DOI: 10.1007/s10620-009-0864-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
91 Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: Where do we go from here? Dig Dis. 2006;24:11-46. [PMID: 16699262 DOI: 10.1159/000091298] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]